3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Breast
1
Conditions
Ventricular Dysfunction
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Hypertension
1
Essential Hypertension
1
Cardiotoxicity
1
Breast Neoplasms
1
Interventions
Rituximab
59
Cyclophosphamide
35
Vincristine
28
Doxorubicin
24
Prednisone
22
Bendamustine Hydrochloride
17
Etoposide
15
Radiotherapy
12
Cytarabine
10
Peripheral Blood Stem Cell Transplantation
8
Filgrastim
8
ibrutinib
7
VAP-cyclo protocol
7
Prednisolone
7
Methotrexate
7
Granulocyte Colony-Stimulating Factor
7
ibritumomab tiuxetan
6
fludarabine
6
Melphalan
6
Gemcitabine
6
pirtobrutinib
5
Mitoxantrone
5
Lenalidomide
5
Carmustine
5
Bleomycin
5
pixantrone
4
Mycophenolic Acid
4
Methylprednisolone
4
Ifosfamide
4
Idarubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Non-Hodgkin
×
Enalapril
×
Clear all
NCT03265574
2024-02-20
PROACT
South Tees Hospitals NHS Foundation Trust
Phase 3
Completed
111 enrolled